| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| T-Lymphocytes, Cytotoxic | 38 | 2019 | 1021 | 5.220 |
Why?
|
| Virus Diseases | 21 | 2024 | 392 | 4.890 |
Why?
|
| T-Lymphocytes | 41 | 2024 | 3933 | 3.770 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 39 | 2024 | 6983 | 2.760 |
Why?
|
| Adoptive Transfer | 14 | 2020 | 435 | 2.500 |
Why?
|
| Immunotherapy, Adoptive | 30 | 2024 | 1838 | 1.980 |
Why?
|
| Epstein-Barr Virus Infections | 12 | 2023 | 475 | 1.780 |
Why?
|
| Antigens, Neoplasm | 19 | 2024 | 1590 | 1.730 |
Why?
|
| Adenoviridae | 22 | 2023 | 1510 | 1.720 |
Why?
|
| Adenoviridae Infections | 7 | 2013 | 114 | 1.690 |
Why?
|
| Immunity, Cellular | 6 | 2023 | 442 | 1.620 |
Why?
|
| Herpesvirus 4, Human | 28 | 2023 | 954 | 1.600 |
Why?
|
| Epitopes, T-Lymphocyte | 12 | 2020 | 228 | 1.290 |
Why?
|
| Antigens, Viral | 14 | 2020 | 520 | 1.260 |
Why?
|
| Immunocompromised Host | 9 | 2024 | 722 | 1.090 |
Why?
|
| CD4-Positive T-Lymphocytes | 11 | 2024 | 1053 | 1.080 |
Why?
|
| Lymphocyte Transfusion | 3 | 2021 | 174 | 1.010 |
Why?
|
| Viruses | 2 | 2018 | 156 | 0.980 |
Why?
|
| CD8-Positive T-Lymphocytes | 14 | 2024 | 1656 | 0.970 |
Why?
|
| Antigen-Presenting Cells | 10 | 2014 | 289 | 0.950 |
Why?
|
| Graft vs Leukemia Effect | 3 | 2021 | 107 | 0.950 |
Why?
|
| Transplantation, Homologous | 16 | 2024 | 3033 | 0.870 |
Why?
|
| Immunotherapy | 13 | 2024 | 3534 | 0.870 |
Why?
|
| Leukocytes, Mononuclear | 7 | 2020 | 719 | 0.830 |
Why?
|
| Receptors, Antigen, T-Cell | 10 | 2024 | 1135 | 0.790 |
Why?
|
| Cytomegalovirus | 13 | 2019 | 493 | 0.770 |
Why?
|
| Lymphocyte Activation | 15 | 2019 | 1733 | 0.760 |
Why?
|
| Adenovirus Infections, Human | 3 | 2010 | 55 | 0.700 |
Why?
|
| Viral Matrix Proteins | 12 | 2018 | 182 | 0.690 |
Why?
|
| Dendritic Cells | 11 | 2017 | 1108 | 0.690 |
Why?
|
| Cell- and Tissue-Based Therapy | 8 | 2023 | 381 | 0.680 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2024 | 520 | 0.670 |
Why?
|
| T-Cell Antigen Receptor Specificity | 7 | 2021 | 94 | 0.650 |
Why?
|
| Graft vs Host Disease | 11 | 2024 | 2805 | 0.610 |
Why?
|
| Parainfluenza Virus 3, Human | 1 | 2017 | 13 | 0.590 |
Why?
|
| Respirovirus Infections | 1 | 2017 | 30 | 0.590 |
Why?
|
| DNA Viruses | 2 | 2017 | 45 | 0.580 |
Why?
|
| Metapneumovirus | 1 | 2017 | 57 | 0.570 |
Why?
|
| Paramyxoviridae Infections | 1 | 2017 | 72 | 0.570 |
Why?
|
| Epitopes | 5 | 2018 | 711 | 0.560 |
Why?
|
| Hematologic Neoplasms | 5 | 2015 | 1955 | 0.560 |
Why?
|
| Receptors, Interleukin-7 | 2 | 2014 | 49 | 0.550 |
Why?
|
| Cytotoxicity, Immunologic | 10 | 2017 | 683 | 0.540 |
Why?
|
| Herpesviridae Infections | 2 | 2018 | 181 | 0.530 |
Why?
|
| Salvage Therapy | 2 | 2021 | 2118 | 0.520 |
Why?
|
| Lymphoma | 7 | 2021 | 1514 | 0.520 |
Why?
|
| Humans | 105 | 2024 | 271060 | 0.510 |
Why?
|
| Capsid Proteins | 2 | 2007 | 219 | 0.500 |
Why?
|
| Graft Survival | 1 | 2018 | 1093 | 0.480 |
Why?
|
| Interleukin-4 Receptor alpha Subunit | 1 | 2014 | 15 | 0.470 |
Why?
|
| Graft Rejection | 1 | 2018 | 866 | 0.450 |
Why?
|
| Cytomegalovirus Infections | 4 | 2013 | 484 | 0.440 |
Why?
|
| Herpesvirus 6, Human | 2 | 2017 | 81 | 0.440 |
Why?
|
| Cell Culture Techniques | 8 | 2019 | 580 | 0.440 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2024 | 7245 | 0.420 |
Why?
|
| Tumor Microenvironment | 5 | 2024 | 2992 | 0.420 |
Why?
|
| Roseolovirus Infections | 1 | 2012 | 39 | 0.410 |
Why?
|
| Cells, Cultured | 10 | 2012 | 5783 | 0.390 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2015 | 455 | 0.380 |
Why?
|
| Epstein-Barr Virus Nuclear Antigens | 4 | 2018 | 76 | 0.380 |
Why?
|
| Virus Activation | 1 | 2012 | 236 | 0.370 |
Why?
|
| Monocytes | 3 | 2012 | 787 | 0.370 |
Why?
|
| Neoplasms, Experimental | 1 | 2014 | 791 | 0.360 |
Why?
|
| Recombinant Fusion Proteins | 6 | 2017 | 1666 | 0.350 |
Why?
|
| T-Lymphocyte Subsets | 4 | 2014 | 595 | 0.350 |
Why?
|
| Interleukin-12 | 2 | 2008 | 267 | 0.340 |
Why?
|
| Tissue Donors | 5 | 2021 | 812 | 0.330 |
Why?
|
| BK Virus | 3 | 2023 | 126 | 0.330 |
Why?
|
| Liver Transplantation | 1 | 2018 | 1184 | 0.330 |
Why?
|
| Antigen Presentation | 6 | 2024 | 289 | 0.320 |
Why?
|
| Genetic Therapy | 7 | 2024 | 1732 | 0.320 |
Why?
|
| Genetic Vectors | 8 | 2014 | 1884 | 0.320 |
Why?
|
| Multiple Myeloma | 1 | 2020 | 2321 | 0.320 |
Why?
|
| DNA, Viral | 2 | 2009 | 763 | 0.310 |
Why?
|
| Genetic Engineering | 3 | 2019 | 299 | 0.310 |
Why?
|
| Child, Preschool | 13 | 2023 | 16930 | 0.310 |
Why?
|
| Myelodysplastic Syndromes | 2 | 2021 | 3148 | 0.310 |
Why?
|
| Immunophenotyping | 9 | 2019 | 1730 | 0.300 |
Why?
|
| Cross Reactions | 2 | 2004 | 269 | 0.280 |
Why?
|
| Transgenes | 3 | 2014 | 589 | 0.280 |
Why?
|
| Adolescent | 16 | 2021 | 32553 | 0.280 |
Why?
|
| Cord Blood Stem Cell Transplantation | 2 | 2023 | 372 | 0.270 |
Why?
|
| Transplant Recipients | 2 | 2020 | 337 | 0.270 |
Why?
|
| Allografts | 2 | 2021 | 684 | 0.270 |
Why?
|
| Child | 18 | 2023 | 30372 | 0.270 |
Why?
|
| Immune System Diseases | 1 | 2006 | 65 | 0.260 |
Why?
|
| Coculture Techniques | 5 | 2019 | 635 | 0.260 |
Why?
|
| Interferon-gamma | 6 | 2020 | 1184 | 0.250 |
Why?
|
| Lymphocyte Depletion | 4 | 2012 | 311 | 0.250 |
Why?
|
| Lymphoproliferative Disorders | 2 | 2014 | 383 | 0.250 |
Why?
|
| Immunodominant Epitopes | 2 | 2017 | 64 | 0.250 |
Why?
|
| Transduction, Genetic | 7 | 2014 | 496 | 0.240 |
Why?
|
| Immunologic Memory | 5 | 2019 | 380 | 0.240 |
Why?
|
| Th1 Cells | 3 | 2020 | 260 | 0.240 |
Why?
|
| Neoplasms | 6 | 2022 | 15861 | 0.230 |
Why?
|
| Cell Communication | 1 | 2007 | 520 | 0.230 |
Why?
|
| Hodgkin Disease | 5 | 2014 | 1487 | 0.230 |
Why?
|
| DNA Virus Infections | 2 | 2017 | 27 | 0.230 |
Why?
|
| Infant | 8 | 2023 | 13876 | 0.230 |
Why?
|
| Male | 28 | 2024 | 128513 | 0.220 |
Why?
|
| Stem Cell Transplantation | 2 | 2009 | 1424 | 0.220 |
Why?
|
| Fetal Blood | 3 | 2010 | 503 | 0.200 |
Why?
|
| Oncolytic Viruses | 1 | 2024 | 165 | 0.200 |
Why?
|
| Female | 27 | 2024 | 148622 | 0.200 |
Why?
|
| Fas Ligand Protein | 1 | 2022 | 155 | 0.200 |
Why?
|
| Adult | 20 | 2024 | 81619 | 0.200 |
Why?
|
| Virus Latency | 2 | 2002 | 79 | 0.200 |
Why?
|
| Leukemia, Myeloid | 2 | 2020 | 994 | 0.200 |
Why?
|
| Receptors, TNF-Related Apoptosis-Inducing Ligand | 1 | 2021 | 64 | 0.200 |
Why?
|
| Recurrence | 7 | 2022 | 4884 | 0.190 |
Why?
|
| Young Adult | 7 | 2021 | 22062 | 0.190 |
Why?
|
| Vaccination | 3 | 2023 | 1154 | 0.190 |
Why?
|
| Cell Line | 8 | 2013 | 5437 | 0.190 |
Why?
|
| Cell Line, Tumor | 16 | 2020 | 14881 | 0.190 |
Why?
|
| Flow Cytometry | 6 | 2012 | 3086 | 0.180 |
Why?
|
| Respiratory Syncytial Virus, Human | 1 | 2023 | 215 | 0.180 |
Why?
|
| Myeloid-Derived Suppressor Cells | 1 | 2021 | 103 | 0.180 |
Why?
|
| Pancreatic Neoplasms | 4 | 2024 | 5237 | 0.180 |
Why?
|
| Transplantation Immunology | 2 | 2012 | 109 | 0.180 |
Why?
|
| Interleukin-4 | 2 | 2018 | 292 | 0.180 |
Why?
|
| Smallpox | 1 | 2020 | 10 | 0.180 |
Why?
|
| Single-Chain Antibodies | 2 | 2011 | 60 | 0.180 |
Why?
|
| Peptides | 7 | 2024 | 1529 | 0.180 |
Why?
|
| Amino Acid Sequence | 6 | 2020 | 4641 | 0.180 |
Why?
|
| Cyclin A1 | 1 | 2020 | 7 | 0.180 |
Why?
|
| Cell Proliferation | 10 | 2019 | 7307 | 0.180 |
Why?
|
| Smallpox Vaccine | 1 | 2020 | 42 | 0.180 |
Why?
|
| Leukemia | 3 | 2022 | 1720 | 0.170 |
Why?
|
| Monitoring, Immunologic | 1 | 2020 | 47 | 0.170 |
Why?
|
| Neoplasm Proteins | 5 | 2018 | 3350 | 0.170 |
Why?
|
| HEK293 Cells | 5 | 2018 | 1473 | 0.170 |
Why?
|
| Antiviral Agents | 5 | 2023 | 1254 | 0.170 |
Why?
|
| Immunosuppressive Agents | 2 | 2018 | 1444 | 0.170 |
Why?
|
| Respiratory Syncytial Virus Infections | 1 | 2023 | 430 | 0.160 |
Why?
|
| Viral Load | 2 | 2018 | 482 | 0.160 |
Why?
|
| Killer Cells, Natural | 2 | 2022 | 958 | 0.160 |
Why?
|
| Feasibility Studies | 5 | 2017 | 2347 | 0.160 |
Why?
|
| Thrombocytopenia | 1 | 2024 | 871 | 0.160 |
Why?
|
| Herpesvirus 3, Human | 1 | 2018 | 44 | 0.160 |
Why?
|
| Virus Replication | 2 | 2020 | 761 | 0.160 |
Why?
|
| Lipopolysaccharide Receptors | 2 | 2009 | 91 | 0.160 |
Why?
|
| Antibodies, Viral | 2 | 2023 | 1295 | 0.150 |
Why?
|
| Anemia | 1 | 2024 | 730 | 0.150 |
Why?
|
| Interleukin-7 | 2 | 2009 | 93 | 0.150 |
Why?
|
| Animals | 19 | 2021 | 62824 | 0.150 |
Why?
|
| Herpesviridae | 1 | 2018 | 41 | 0.150 |
Why?
|
| Elephants | 1 | 2018 | 37 | 0.150 |
Why?
|
| Granzymes | 1 | 2017 | 95 | 0.150 |
Why?
|
| Viremia | 1 | 2018 | 181 | 0.140 |
Why?
|
| Blood Platelets | 2 | 2019 | 683 | 0.140 |
Why?
|
| Middle Aged | 13 | 2024 | 90103 | 0.140 |
Why?
|
| Lymphocyte Subsets | 1 | 2017 | 138 | 0.140 |
Why?
|
| Adenoviruses, Human | 3 | 2017 | 191 | 0.130 |
Why?
|
| Cytokines | 4 | 2019 | 2837 | 0.130 |
Why?
|
| Mucin-1 | 2 | 2013 | 164 | 0.130 |
Why?
|
| Epitope Mapping | 3 | 2013 | 110 | 0.130 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2017 | 426 | 0.130 |
Why?
|
| Viral Proteins | 1 | 2018 | 494 | 0.130 |
Why?
|
| Peptide Fragments | 5 | 2013 | 1328 | 0.130 |
Why?
|
| HLA Antigens | 4 | 2012 | 575 | 0.130 |
Why?
|
| Membrane Glycoproteins | 2 | 2013 | 1107 | 0.130 |
Why?
|
| Xenograft Model Antitumor Assays | 4 | 2019 | 3929 | 0.130 |
Why?
|
| Conserved Sequence | 2 | 2007 | 498 | 0.120 |
Why?
|
| Mice, SCID | 3 | 2014 | 1855 | 0.120 |
Why?
|
| Antilymphocyte Serum | 1 | 2015 | 237 | 0.120 |
Why?
|
| Receptors, LDL | 1 | 2014 | 122 | 0.110 |
Why?
|
| Cell Engineering | 1 | 2013 | 35 | 0.110 |
Why?
|
| Hyperlipoproteinemia Type II | 1 | 2014 | 88 | 0.110 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2016 | 255 | 0.110 |
Why?
|
| Caspase 9 | 1 | 2014 | 191 | 0.110 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 6 | 2013 | 1538 | 0.110 |
Why?
|
| Prospective Studies | 4 | 2023 | 13375 | 0.110 |
Why?
|
| Flutamide | 1 | 2013 | 51 | 0.110 |
Why?
|
| Peptide Library | 2 | 2011 | 166 | 0.110 |
Why?
|
| Pilot Projects | 1 | 2020 | 2852 | 0.110 |
Why?
|
| Papillomavirus E7 Proteins | 1 | 2013 | 64 | 0.110 |
Why?
|
| Species Specificity | 1 | 2014 | 809 | 0.110 |
Why?
|
| Common Variable Immunodeficiency | 1 | 2013 | 32 | 0.110 |
Why?
|
| Blood Donors | 2 | 2011 | 173 | 0.110 |
Why?
|
| Transforming Growth Factor beta | 1 | 2018 | 1133 | 0.110 |
Why?
|
| Myeloablative Agonists | 1 | 2015 | 386 | 0.110 |
Why?
|
| Breast Neoplasms | 3 | 2024 | 16196 | 0.100 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2014 | 194 | 0.100 |
Why?
|
| Prognosis | 5 | 2021 | 22464 | 0.100 |
Why?
|
| Gene Transfer Techniques | 3 | 2010 | 812 | 0.100 |
Why?
|
| Immunoenzyme Techniques | 2 | 2011 | 1214 | 0.100 |
Why?
|
| Oncogene Proteins, Viral | 1 | 2013 | 147 | 0.100 |
Why?
|
| Treatment Outcome | 7 | 2024 | 33850 | 0.100 |
Why?
|
| Gene Expression | 4 | 2017 | 3679 | 0.100 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2017 | 1617 | 0.100 |
Why?
|
| Histocompatibility Testing | 2 | 2013 | 483 | 0.100 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2017 | 803 | 0.100 |
Why?
|
| CD40 Ligand | 1 | 2012 | 130 | 0.100 |
Why?
|
| Adaptive Immunity | 1 | 2012 | 149 | 0.100 |
Why?
|
| Combined Modality Therapy | 2 | 2021 | 9045 | 0.100 |
Why?
|
| Receptors, Antigen | 1 | 2011 | 68 | 0.100 |
Why?
|
| HLA-A Antigens | 3 | 2011 | 105 | 0.100 |
Why?
|
| Neuroblastoma | 1 | 2017 | 701 | 0.090 |
Why?
|
| Human papillomavirus 16 | 1 | 2013 | 256 | 0.090 |
Why?
|
| Chills | 1 | 2010 | 12 | 0.090 |
Why?
|
| Home Infusion Therapy | 1 | 2010 | 10 | 0.090 |
Why?
|
| Postoperative Nausea and Vomiting | 1 | 2010 | 43 | 0.090 |
Why?
|
| Nephritis, Interstitial | 1 | 2011 | 74 | 0.090 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2014 | 2899 | 0.090 |
Why?
|
| B7-1 Antigen | 2 | 2007 | 86 | 0.090 |
Why?
|
| Tumor Escape | 2 | 2013 | 248 | 0.080 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2013 | 1119 | 0.080 |
Why?
|
| Receptors, Virus | 1 | 2010 | 154 | 0.080 |
Why?
|
| Drugs, Investigational | 1 | 2010 | 130 | 0.080 |
Why?
|
| Oncolytic Virotherapy | 1 | 2012 | 235 | 0.080 |
Why?
|
| Antigens | 1 | 2010 | 288 | 0.080 |
Why?
|
| Postoperative Complications | 2 | 2018 | 5683 | 0.080 |
Why?
|
| In Vitro Techniques | 3 | 2010 | 1745 | 0.080 |
Why?
|
| Risk Factors | 2 | 2018 | 17829 | 0.080 |
Why?
|
| Molecular Sequence Data | 3 | 2005 | 6784 | 0.080 |
Why?
|
| Leukemia, B-Cell | 1 | 2010 | 114 | 0.080 |
Why?
|
| CD3 Complex | 1 | 2009 | 322 | 0.080 |
Why?
|
| Retinoblastoma | 1 | 2010 | 194 | 0.080 |
Why?
|
| Bone Marrow Transplantation | 1 | 2014 | 1773 | 0.080 |
Why?
|
| Plasmids | 1 | 2010 | 952 | 0.080 |
Why?
|
| Nasopharyngeal Neoplasms | 2 | 2014 | 337 | 0.080 |
Why?
|
| Forkhead Transcription Factors | 1 | 2012 | 773 | 0.080 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2011 | 1346 | 0.080 |
Why?
|
| Mice | 9 | 2021 | 36037 | 0.080 |
Why?
|
| Antigens, CD34 | 1 | 2009 | 642 | 0.070 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2013 | 853 | 0.070 |
Why?
|
| Fever | 1 | 2010 | 515 | 0.070 |
Why?
|
| Stem Cells | 1 | 2014 | 1231 | 0.070 |
Why?
|
| Cell Line, Transformed | 3 | 2014 | 431 | 0.070 |
Why?
|
| Follow-Up Studies | 3 | 2018 | 15249 | 0.070 |
Why?
|
| Mutation | 2 | 2024 | 15861 | 0.070 |
Why?
|
| Interleukins | 1 | 2009 | 341 | 0.070 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2020 | 10351 | 0.070 |
Why?
|
| Prostatic Neoplasms | 2 | 2013 | 5992 | 0.070 |
Why?
|
| Immunoglobulins | 1 | 2007 | 291 | 0.070 |
Why?
|
| Transplantation Conditioning | 1 | 2015 | 2359 | 0.060 |
Why?
|
| Virion | 2 | 2020 | 187 | 0.060 |
Why?
|
| Neoplastic Stem Cells | 2 | 2011 | 1469 | 0.060 |
Why?
|
| K562 Cells | 3 | 2011 | 345 | 0.060 |
Why?
|
| Adenocarcinoma | 1 | 2024 | 7936 | 0.060 |
Why?
|
| Aged | 6 | 2024 | 73250 | 0.060 |
Why?
|
| Azacitidine | 1 | 2011 | 1219 | 0.060 |
Why?
|
| Repressor Proteins | 1 | 2013 | 1729 | 0.060 |
Why?
|
| Cell Separation | 3 | 2012 | 616 | 0.060 |
Why?
|
| Cell Transformation, Viral | 1 | 2005 | 174 | 0.060 |
Why?
|
| GPI-Linked Proteins | 2 | 2018 | 227 | 0.060 |
Why?
|
| Brain Neoplasms | 2 | 2012 | 4981 | 0.060 |
Why?
|
| Immune Tolerance | 1 | 2007 | 431 | 0.060 |
Why?
|
| HLA-B Antigens | 1 | 2024 | 56 | 0.060 |
Why?
|
| Cell Differentiation | 2 | 2019 | 4190 | 0.060 |
Why?
|
| Feces | 1 | 2007 | 865 | 0.050 |
Why?
|
| Biomarkers | 2 | 2019 | 5107 | 0.050 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2009 | 1373 | 0.050 |
Why?
|
| Tumor Cells, Cultured | 4 | 2013 | 5834 | 0.050 |
Why?
|
| Cell Survival | 2 | 2019 | 3085 | 0.050 |
Why?
|
| WT1 Proteins | 2 | 2013 | 107 | 0.050 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2024 | 16603 | 0.050 |
Why?
|
| Albumins | 1 | 2024 | 267 | 0.050 |
Why?
|
| Disease Models, Animal | 3 | 2021 | 7470 | 0.050 |
Why?
|
| Lymphocytes | 2 | 2023 | 1269 | 0.050 |
Why?
|
| Antigens, CD | 1 | 2007 | 1435 | 0.050 |
Why?
|
| Homeostasis | 1 | 2007 | 960 | 0.050 |
Why?
|
| HLA-A2 Antigen | 2 | 2013 | 171 | 0.050 |
Why?
|
| Receptor, ErbB-2 | 1 | 2011 | 2648 | 0.050 |
Why?
|
| Glioblastoma | 1 | 2012 | 1778 | 0.050 |
Why?
|
| Polymerase Chain Reaction | 1 | 2007 | 3492 | 0.050 |
Why?
|
| Vaccinia virus | 1 | 2020 | 85 | 0.040 |
Why?
|
| Receptors, CCR7 | 1 | 2019 | 38 | 0.040 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2011 | 1821 | 0.040 |
Why?
|
| Phosphoproteins | 3 | 2012 | 1229 | 0.040 |
Why?
|
| Bayes Theorem | 1 | 2024 | 1038 | 0.040 |
Why?
|
| Busulfan | 1 | 2023 | 786 | 0.040 |
Why?
|
| CD28 Antigens | 1 | 2019 | 204 | 0.040 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2014 | 9084 | 0.040 |
Why?
|
| Alleles | 1 | 2004 | 2507 | 0.040 |
Why?
|
| Asia | 1 | 2018 | 153 | 0.040 |
Why?
|
| Antigens, CD19 | 2 | 2011 | 584 | 0.040 |
Why?
|
| Gene Editing | 1 | 2019 | 231 | 0.040 |
Why?
|
| Phenotype | 2 | 2024 | 6464 | 0.030 |
Why?
|
| Organ Specificity | 1 | 2018 | 751 | 0.030 |
Why?
|
| Vaccines, Attenuated | 1 | 2017 | 190 | 0.030 |
Why?
|
| Paclitaxel | 1 | 2024 | 2099 | 0.030 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2010 | 5429 | 0.030 |
Why?
|
| Immunohistochemistry | 3 | 2011 | 7815 | 0.030 |
Why?
|
| Cyclophosphamide | 1 | 2023 | 3231 | 0.030 |
Why?
|
| Up-Regulation | 2 | 2011 | 2466 | 0.030 |
Why?
|
| Injections, Intra-Arterial | 1 | 2014 | 55 | 0.030 |
Why?
|
| Balloon Occlusion | 1 | 2014 | 61 | 0.030 |
Why?
|
| Etanercept | 1 | 2014 | 69 | 0.030 |
Why?
|
| Organic Chemicals | 1 | 2014 | 103 | 0.030 |
Why?
|
| Enzyme Induction | 1 | 2014 | 262 | 0.030 |
Why?
|
| Time Factors | 3 | 2014 | 13112 | 0.030 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2014 | 215 | 0.030 |
Why?
|
| Remission Induction | 1 | 2020 | 3646 | 0.030 |
Why?
|
| Aspergillus fumigatus | 1 | 2014 | 138 | 0.030 |
Why?
|
| Hepatic Artery | 1 | 2014 | 256 | 0.030 |
Why?
|
| Colony-Forming Units Assay | 1 | 2013 | 255 | 0.030 |
Why?
|
| Myeloblastin | 1 | 2013 | 64 | 0.030 |
Why?
|
| Leukocyte Elastase | 1 | 2013 | 71 | 0.030 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2013 | 203 | 0.030 |
Why?
|
| Macaca mulatta | 1 | 2014 | 731 | 0.030 |
Why?
|
| Trans-Activators | 1 | 2018 | 1655 | 0.030 |
Why?
|
| Aspergillosis | 1 | 2014 | 249 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2009 | 3653 | 0.030 |
Why?
|
| Haplotypes | 1 | 2014 | 851 | 0.020 |
Why?
|
| Chemokine CCL5 | 1 | 2012 | 77 | 0.020 |
Why?
|
| Muromonab-CD3 | 1 | 2011 | 20 | 0.020 |
Why?
|
| Prednisone | 1 | 2014 | 1039 | 0.020 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2014 | 631 | 0.020 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2014 | 459 | 0.020 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2014 | 319 | 0.020 |
Why?
|
| Risk | 1 | 2015 | 1913 | 0.020 |
Why?
|
| Coxsackie and Adenovirus Receptor-Like Membrane Protein | 1 | 2010 | 40 | 0.020 |
Why?
|
| Androgen Antagonists | 1 | 2013 | 434 | 0.020 |
Why?
|
| T Cell Transcription Factor 1 | 1 | 2009 | 9 | 0.020 |
Why?
|
| Immunoglobulin G | 1 | 2014 | 1143 | 0.020 |
Why?
|
| In Situ Hybridization | 1 | 2012 | 1062 | 0.020 |
Why?
|
| Thymidine Kinase | 1 | 2010 | 224 | 0.020 |
Why?
|
| Blood Cells | 1 | 2010 | 130 | 0.020 |
Why?
|
| Lymphoid Enhancer-Binding Factor 1 | 1 | 2009 | 35 | 0.020 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 1 | 2014 | 388 | 0.020 |
Why?
|
| eIF-2 Kinase | 1 | 2010 | 166 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2010 | 184 | 0.020 |
Why?
|
| Gene Deletion | 1 | 2014 | 1482 | 0.020 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2014 | 504 | 0.020 |
Why?
|
| United States Food and Drug Administration | 1 | 2010 | 334 | 0.020 |
Why?
|
| Lentivirus | 1 | 2009 | 167 | 0.020 |
Why?
|
| Recovery of Function | 1 | 2012 | 691 | 0.020 |
Why?
|
| Mice, Inbred NOD | 1 | 2011 | 911 | 0.020 |
Why?
|
| Culture Media | 1 | 2009 | 338 | 0.020 |
Why?
|
| B-Lymphocytes | 1 | 2015 | 1429 | 0.020 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2014 | 1011 | 0.020 |
Why?
|
| Lymphocyte Count | 1 | 2010 | 485 | 0.020 |
Why?
|
| Telomerase | 1 | 2012 | 533 | 0.020 |
Why?
|
| Eye | 1 | 2010 | 286 | 0.020 |
Why?
|
| Multimodal Imaging | 1 | 2012 | 553 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2010 | 1438 | 0.020 |
Why?
|
| B7-2 Antigen | 1 | 2007 | 53 | 0.020 |
Why?
|
| MART-1 Antigen | 1 | 2007 | 113 | 0.020 |
Why?
|
| Hematopoiesis | 1 | 2009 | 606 | 0.020 |
Why?
|
| Mothers | 1 | 2009 | 418 | 0.020 |
Why?
|
| Interleukin-2 | 1 | 2009 | 891 | 0.020 |
Why?
|
| Neutrophils | 1 | 2009 | 876 | 0.020 |
Why?
|
| CD4 Antigens | 1 | 2005 | 172 | 0.020 |
Why?
|
| Deoxycytidine | 1 | 2010 | 1377 | 0.010 |
Why?
|
| Antibody Specificity | 1 | 2005 | 356 | 0.010 |
Why?
|
| Liver | 1 | 2014 | 3124 | 0.010 |
Why?
|
| Papillomavirus Infections | 1 | 2013 | 1009 | 0.010 |
Why?
|
| Transfection | 1 | 2009 | 3169 | 0.010 |
Why?
|
| Neoplasms, Second Primary | 1 | 2012 | 1379 | 0.010 |
Why?
|
| Epigenesis, Genetic | 1 | 2011 | 1436 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2009 | 2258 | 0.010 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2013 | 1156 | 0.010 |
Why?
|
| Macrophages | 1 | 2010 | 1373 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2015 | 9305 | 0.010 |
Why?
|
| Positron-Emission Tomography | 1 | 2012 | 2198 | 0.010 |
Why?
|
| Gene Targeting | 1 | 2004 | 321 | 0.010 |
Why?
|
| Carcinoma | 1 | 2014 | 2627 | 0.010 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2013 | 1913 | 0.010 |
Why?
|
| Capsid | 1 | 2002 | 178 | 0.010 |
Why?
|
| Molecular Targeted Therapy | 1 | 2011 | 2400 | 0.010 |
Why?
|
| Age Factors | 1 | 2010 | 5487 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2010 | 6485 | 0.010 |
Why?
|
| Models, Biological | 1 | 2009 | 3226 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2010 | 2428 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2018 | 12220 | 0.010 |
Why?
|
| Rats | 1 | 2009 | 6647 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2010 | 6187 | 0.010 |
Why?
|
| Fibroblasts | 1 | 2004 | 1672 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2007 | 3861 | 0.010 |
Why?
|
| Melanoma | 1 | 2014 | 5529 | 0.010 |
Why?
|
| Lymph Nodes | 1 | 2007 | 3067 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2012 | 7786 | 0.010 |
Why?
|
| Apoptosis | 1 | 2009 | 7862 | 0.010 |
Why?
|
| United States | 1 | 2010 | 16011 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2004 | 8580 | 0.010 |
Why?
|